Jelena Grahovac
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jelena Grahovac has a total of 206 co-authors. Here are the top co-authors by number of shared publications:
- Tatjana Srdic-Rajic
Institute for Oncology and Radiology of Serbia, Department of Experimental Oncology, Belgrade, Serbia
8 shared publications - Alan Wells
Department of Pathology, University of Pittsburgh, Pittsburgh, USA
6 shared publications - Marija Ostojić
Department of Experimental Oncology, Institute for Oncology and Radiology of Serbia, 11000 Belgrade, Serbia
6 shared publications - Marijana Pavlović
Department of Experimental Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
6 shared publications - Kristina Živić
Department of Experimental Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
5 shared publications Marija Ostojić
Institute for Oncology and Radiology of Serbia
4 shared publications
Latest Publications
- 25 October 2026
- Published by Springer Nature
- Vol. 3089, 133-141
Skin Organ Constructs for In Vitro Modeling of Melanoma Invasion
Melanoma progression from an in situ lesion to an invasive dermal tumor is strongly associated with poor patient prognosis, with depth of invasion serving as a predictor of survival. Increasing evidence indicates that remodeling of the extracellular matrix (ECM) plays a central role in this transition by altering both mechanical and biochemical cues within the tumor microenvironment. To facilitate mechanistic studies of ECM-mediated melanoma invasion, we developed a reproducible in vitro skin organ construct (SOC) model that recapitulates key structural and cellular features of human skin. The SOC system is assembled using a two-layer collagen-based dermal equivalent containing primary human dermal fibroblasts, overlaid with normal human epidermal keratinocytes to generate a stratified epidermis. Melanoma cells are subsequently seeded onto the reconstructed epidermal surface and cultured under defined conditions, including staged modulation of epidermal growth factor and exposure to an air–liquid interface to promote keratinization. The model permits incorporation of defined ECM components or genetically modified melanoma cells to evaluate their impact on tumor invasion. Melanoma progression is assessed by measuring radial growth and quantifying invasion depth and patterns in paraffin-embedded sections using histological and immunohistochemical analyses. This SOC platform provides a physiologically relevant and customizable system to investigate ECM-driven mechanisms of melanoma invasion and to evaluate candidate therapeutic targets that modulate tumor–microenvironment interactions.
- 25 October 2026
- Published by Springer Nature
- Vol. 3089, 133-141
Skin Organ Constructs for In Vitro Modeling of Melanoma Invasion
Melanoma progression from an in situ lesion to an invasive dermal tumor is strongly associated with poor patient prognosis, with depth of invasion serving as a predictor of survival. Increasing evidence indicates that remodeling of the extracellular matrix (ECM) plays a central role in this transition by altering both mechanical and biochemical cues within the tumor microenvironment. To facilitate mechanistic studies of ECM-mediated melanoma invasion, we developed a reproducible in vitro skin organ construct (SOC) model that recapitulates key structural and cellular features of human skin. The SOC system is assembled using a two-layer collagen-based dermal equivalent containing primary human dermal fibroblasts, overlaid with normal human epidermal keratinocytes to generate a stratified epidermis. Melanoma cells are subsequently seeded onto the reconstructed epidermal surface and cultured under defined conditions, including staged modulation of epidermal growth factor and exposure to an air–liquid interface to promote keratinization. The model permits incorporation of defined ECM components or genetically modified melanoma cells to evaluate their impact on tumor invasion. Melanoma progression is assessed by measuring radial growth and quantifying invasion depth and patterns in paraffin-embedded sections using histological and immunohistochemical analyses. This SOC platform provides a physiologically relevant and customizable system to investigate ECM-driven mechanisms of melanoma invasion and to evaluate candidate therapeutic targets that modulate tumor–microenvironment interactions.
- 25 October 2026
- Published by Springer Nature
- Vol. 3089, 73-83
A Fluorescence-Based Assay for Measuring Glucose Uptake in Living Melanoma Cells
Melanoma cells have high glycolytic capacity. Glucose uptake is a key rate-limiting step in glucose utilization. Here we describe a simple protocol for measuring direct glucose uptake in living melanoma cells by flow cytometry.
- 25 October 2026
- Published by Springer Nature
- Vol. 3089, 73-83
A Fluorescence-Based Assay for Measuring Glucose Uptake in Living Melanoma Cells
Melanoma cells have high glycolytic capacity. Glucose uptake is a key rate-limiting step in glucose utilization. Here we describe a simple protocol for measuring direct glucose uptake in living melanoma cells by flow cytometry.
- Open Access
Repurposing Rilmenidine as a Potential Antimetastatic Therapy Targeting Nischarin in Pancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancer types with a dismal prognosis, where early metastatic dissemination and rich desmoplastic stroma limit the therapeutic efficacy. Nischarin (NISCH)/Imidazoline-1 receptor (IR-1) is a potential tumor suppressor that is involved in the regulation of cell migration, invasion, and cytoskeletal organization. Importantly, several clinically approved agonists have been shown to target this receptor. This study aimed to examine NISCH expression in PDAC and the effects of its agonists with the intent of drug repurposing. NISCH was expressed in PDAC tumor tissue, in both the epithelial and stromal compartments of tumors, and higher NISCH expression was associated with longer patient survival. Out of the three tested NISCH agonists, moxonidine, clonidine and rilmenidine, rilmenidine was the only one affecting cancer cell viability and at high doses induced cancer cell apoptosis. Transcriptome analysis of rilmenidine-treated PDAC cells revealed changes associated with cytoskeletal organization, translating into decreased adhesion and migration in vitro. In cancer-associated fibroblasts (CAFs), rilmenidine treatment decreased the expression of activation markers and limited cancer cell-CAF cytokine communication in the co-culture. Ultimately, in the in vivo tumor xenograft zebrafish model, rilmenidine reduced the metastatic spread of pancreatic cancer cells. Our results suggest that the NISCH agonist rilmenidine is a promising candidate for drug repurposing as an antimetastatic agent in PDAC, and that NISCH can be a potential target for the development of new PDAC therapeutics.
Open AccessRepurposing Rilmenidine as a Potential Antimetastatic Therapy Targeting Nischarin in Pancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancer types with a dismal prognosis, where early metastatic dissemination and rich desmoplastic stroma limit the therapeutic efficacy. Nischarin (NISCH)/Imidazoline-1 receptor (IR-1) is a potential tumor suppressor that is involved in the regulation of cell migration, invasion, and cytoskeletal organization. Importantly, several clinically approved agonists have been shown to target this receptor. This study aimed to examine NISCH expression in PDAC and the effects of its agonists with the intent of drug repurposing. NISCH was expressed in PDAC tumor tissue, in both the epithelial and stromal compartments of tumors, and higher NISCH expression was associated with longer patient survival. Out of the three tested NISCH agonists, moxonidine, clonidine and rilmenidine, rilmenidine was the only one affecting cancer cell viability and at high doses induced cancer cell apoptosis. Transcriptome analysis of rilmenidine-treated PDAC cells revealed changes associated with cytoskeletal organization, translating into decreased adhesion and migration in vitro. In cancer-associated fibroblasts (CAFs), rilmenidine treatment decreased the expression of activation markers and limited cancer cell-CAF cytokine communication in the co-culture. Ultimately, in the in vivo tumor xenograft zebrafish model, rilmenidine reduced the metastatic spread of pancreatic cancer cells. Our results suggest that the NISCH agonist rilmenidine is a promising candidate for drug repurposing as an antimetastatic agent in PDAC, and that NISCH can be a potential target for the development of new PDAC therapeutics.
- 17 January 2026
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 426, 111925
The in vitro assessment of the prooxidative action of the novel aroylacrylic acid phenylamides in A549 and MCF7 cancer cell lines
- 17 January 2026
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 426, 111925
The in vitro assessment of the prooxidative action of the novel aroylacrylic acid phenylamides in A549 and MCF7 cancer cell lines
- Open Access
- 1 January 2026
- Published by National Library of Serbia in Journal of the Serbian Chemical Society
- No. 00,p. 57
4-aminoquinolines promote redox-dependent ferroptosis sensitization in pancreatic ductal adenocarcinoma cells
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer marked by oxidative stress, metabolic rewiring, and resistance to cell death. Ferroptosis, a regulated cell death driven by iron-dependent lipid peroxidation, represents a promising therapeutic vulnerability in PDAC; however, intrinsic resistance to ferroptosis limits its therapeutic exploitation. This study shows that 4-aminoquinoline derivatives sensitize PDAC cell lines (MIA PaCa-2 and PANC-1) to erastin-induced ferroptotic cell death. Ferroptosis sensitization occurred independently of caspase-3/7 activation and was associated with increased ROS production, mitochondrial oxidative stress, lipid peroxidation, and redox imbalance. Importantly, sensitivity to ferroptosis was accompanied by decreased GSH levels, reduced intracellular cystine levels, and differential regulation of the KEAP1-Nrf2-p62 axis. While PANC-1 cells exhibited enhanced oxidative stress and KEAP1 upregulation, MIA PaCa-2 cells maintained relative redox homeostasis unless exposed to combined treatment conditions. To our knowledge, this study provides the first evidence that 4- aminoquinoline derivatives promote sensitization to ferroptosis in PDAC and highlights the therapeutic potential of targeting redox metabolism and stress-adaptive signaling to overcome resistance to therapy in pancreatic cancer.
- 1 January 2026
- Published by National Library of Serbia in Journal of the Serbian Chemical Society
- No. 00,p. 57
Open Access4-aminoquinolines promote redox-dependent ferroptosis sensitization in pancreatic ductal adenocarcinoma cells
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer marked by oxidative stress, metabolic rewiring, and resistance to cell death. Ferroptosis, a regulated cell death driven by iron-dependent lipid peroxidation, represents a promising therapeutic vulnerability in PDAC; however, intrinsic resistance to ferroptosis limits its therapeutic exploitation. This study shows that 4-aminoquinoline derivatives sensitize PDAC cell lines (MIA PaCa-2 and PANC-1) to erastin-induced ferroptotic cell death. Ferroptosis sensitization occurred independently of caspase-3/7 activation and was associated with increased ROS production, mitochondrial oxidative stress, lipid peroxidation, and redox imbalance. Importantly, sensitivity to ferroptosis was accompanied by decreased GSH levels, reduced intracellular cystine levels, and differential regulation of the KEAP1-Nrf2-p62 axis. While PANC-1 cells exhibited enhanced oxidative stress and KEAP1 upregulation, MIA PaCa-2 cells maintained relative redox homeostasis unless exposed to combined treatment conditions. To our knowledge, this study provides the first evidence that 4- aminoquinoline derivatives promote sensitization to ferroptosis in PDAC and highlights the therapeutic potential of targeting redox metabolism and stress-adaptive signaling to overcome resistance to therapy in pancreatic cancer.
- Open Access
- 1 January 2026
- Published by National Library of Serbia in Archives of Biological Sciences
- No. 00,p. 22
Rilmenidine modulates intracellular accumulation of ABC transporter substrates in pancreatic ductal adenocarcinoma cells
The antihypertensive drug rilmenidine has been investigated as a candidate for drug repurposing in oncology for its cytotoxic and antimetastatic properties through activation of the tumor suppressor nischarin. We recently observed that the presence of rilmenidine was associated with fluorescent dye accumulation in pancreatic ductal adenocarcinoma (PDAC) cell lines. This study was designed to examine whether rilmenidine has the potential to modulate the accumulation of dyes and chemotherapeutics known to be ABC transporter substrates. We screened a panel of PDAC cell lines for expression of MDR-related ABC transporters (ABCB1, ABCC1, ABCC2, and ABCG2) and selected PANC-1, MIA PaCa-2, and AsPC-1 cell lines as model systems. We found that rilmenidine treatment attenuated the efflux of calcein, Hoechst 33342, and doxorubicin, implying modulation of ABCB1, ABCC1, and ABCC2 pump activity in a manner comparable, but weaker than known inhibitors. In silico examination suggested that rilmenidine could bind to the ligand pockets of these pumps. Finally, rilmenidine potentiated the effects of 5-fluorouracil (5-FU) and paclitaxel in PDAC cells measured in vitro. These findings suggest that rilmenidine can modulate MDR-associated ABC transporter activity and should be considered when evaluating its potential for repurposing in cancer therapy.
- 1 January 2026
- Published by National Library of Serbia in Archives of Biological Sciences
- No. 00,p. 22
Open AccessRilmenidine modulates intracellular accumulation of ABC transporter substrates in pancreatic ductal adenocarcinoma cells
The antihypertensive drug rilmenidine has been investigated as a candidate for drug repurposing in oncology for its cytotoxic and antimetastatic properties through activation of the tumor suppressor nischarin. We recently observed that the presence of rilmenidine was associated with fluorescent dye accumulation in pancreatic ductal adenocarcinoma (PDAC) cell lines. This study was designed to examine whether rilmenidine has the potential to modulate the accumulation of dyes and chemotherapeutics known to be ABC transporter substrates. We screened a panel of PDAC cell lines for expression of MDR-related ABC transporters (ABCB1, ABCC1, ABCC2, and ABCG2) and selected PANC-1, MIA PaCa-2, and AsPC-1 cell lines as model systems. We found that rilmenidine treatment attenuated the efflux of calcein, Hoechst 33342, and doxorubicin, implying modulation of ABCB1, ABCC1, and ABCC2 pump activity in a manner comparable, but weaker than known inhibitors. In silico examination suggested that rilmenidine could bind to the ligand pockets of these pumps. Finally, rilmenidine potentiated the effects of 5-fluorouracil (5-FU) and paclitaxel in PDAC cells measured in vitro. These findings suggest that rilmenidine can modulate MDR-associated ABC transporter activity and should be considered when evaluating its potential for repurposing in cancer therapy.
- Open Access
Newly Synthesized Telmisartan–Amino Acid Conjugates Exhibit Enhanced Cytotoxic Effects in Malignant Melanoma Cells
Telmisartan, an angiotensin II type 1 receptor (AT1R) antagonist, possesses cytotoxic activity towards BRAF-mutated melanoma cell lines. However, its antihypertensive effects limit its use in the population of normotensive patients. To mitigate this shortcoming, a group of eight telmisartan–amino acid conjugates, designed to have reduced or no AT1R affinity with enhanced cellular uptake, were synthesized by the coupling reaction in yields ranging from 34% to 60%. Their cytotoxicity was tested on BRAF V600E-mutated melanoma cell lines (A375 and 518A2), and compounds 1, 3, and 8 stood out as the best candidates. These three compounds were also tested on the vemurafenib-resistant (A375R) and normal (HaCaT and MRC-5) cell lines, and compound 8 showed better cytotoxicity (IC50 = 8.84 ± 1.24 µM) and selectivity (>3.50) when compared to telmisartan (IC50 = 29.23 ± 3.88, selectivity > 2.40). The cellular uptake of compounds 1 and 8 was significantly higher than telmisartan, with substantial accumulation in the membrane and nuclear compartments. Unlike telmisartan, compounds 1, 3, and 8 did not inhibit angiotensin II-induced Ca2+ signaling, which indicates diminished AT1R binding. All three compounds induced cell cycle arrest and disrupted mitochondrial morphology and membrane potential. These findings highlight their potential as non-antihypertensive telmisartan derivatives for melanoma therapy.
Open AccessNewly Synthesized Telmisartan–Amino Acid Conjugates Exhibit Enhanced Cytotoxic Effects in Malignant Melanoma Cells
Telmisartan, an angiotensin II type 1 receptor (AT1R) antagonist, possesses cytotoxic activity towards BRAF-mutated melanoma cell lines. However, its antihypertensive effects limit its use in the population of normotensive patients. To mitigate this shortcoming, a group of eight telmisartan–amino acid conjugates, designed to have reduced or no AT1R affinity with enhanced cellular uptake, were synthesized by the coupling reaction in yields ranging from 34% to 60%. Their cytotoxicity was tested on BRAF V600E-mutated melanoma cell lines (A375 and 518A2), and compounds 1, 3, and 8 stood out as the best candidates. These three compounds were also tested on the vemurafenib-resistant (A375R) and normal (HaCaT and MRC-5) cell lines, and compound 8 showed better cytotoxicity (IC50 = 8.84 ± 1.24 µM) and selectivity (>3.50) when compared to telmisartan (IC50 = 29.23 ± 3.88, selectivity > 2.40). The cellular uptake of compounds 1 and 8 was significantly higher than telmisartan, with substantial accumulation in the membrane and nuclear compartments. Unlike telmisartan, compounds 1, 3, and 8 did not inhibit angiotensin II-induced Ca2+ signaling, which indicates diminished AT1R binding. All three compounds induced cell cycle arrest and disrupted mitochondrial morphology and membrane potential. These findings highlight their potential as non-antihypertensive telmisartan derivatives for melanoma therapy.
- Open Access
Nischarin agonist rilmenidine shows antimetastatic potential in pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancer types with a dismal prognosis. Early metastatic dissemination and rich desmoplastic stroma limit therapeutic efficacy, and the discovery of new treatment approaches that will target these obstacles is of great importance. Nischarin (NISCH)/Imidazoline-1 receptor (IR-1) is a potential tumor suppressor, that is involved in the regulation of cell migration, invasion, and cytoskeletal organization. Importantly, several FDA-approved agonists target this receptor. This study aimed to examine the expression of NISCH in PDAC and the effects of its agonists with the intent of drug repurposing. NISCH was expressed in PDAC tumor tissue, in both the epithelial and stromal compartments of tumors, and higher NISCH expression was associated with longer patient survival. Out of the three tested NISCH agonists, rilmenidine was the most potent and could induce cancer cell apoptosis. Rilmenidine treatment induced transcriptional changes in cancer cells associated with so far reported NISCH function and decreased their adhesion and migration in vitro . In CAFs, rilmenidine treatment decreased the expression of activation markers and limited cancer cell-CAF cytokine communication in co-culture. Ultimately, in the in vivo tumor xenograft zebrafish model, rilmenidine reduced the metastatic spread of pancreatic cancer cells. Our results suggest that NISCH agonist rilmenidine is a promising candidate for drug repurposing as an antimetastatic agent in PDAC and that NISCH can be a potential target for the development of new PDAC therapeutics.
Open AccessNischarin agonist rilmenidine shows antimetastatic potential in pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancer types with a dismal prognosis. Early metastatic dissemination and rich desmoplastic stroma limit therapeutic efficacy, and the discovery of new treatment approaches that will target these obstacles is of great importance. Nischarin (NISCH)/Imidazoline-1 receptor (IR-1) is a potential tumor suppressor, that is involved in the regulation of cell migration, invasion, and cytoskeletal organization. Importantly, several FDA-approved agonists target this receptor. This study aimed to examine the expression of NISCH in PDAC and the effects of its agonists with the intent of drug repurposing. NISCH was expressed in PDAC tumor tissue, in both the epithelial and stromal compartments of tumors, and higher NISCH expression was associated with longer patient survival. Out of the three tested NISCH agonists, rilmenidine was the most potent and could induce cancer cell apoptosis. Rilmenidine treatment induced transcriptional changes in cancer cells associated with so far reported NISCH function and decreased their adhesion and migration in vitro . In CAFs, rilmenidine treatment decreased the expression of activation markers and limited cancer cell-CAF cytokine communication in co-culture. Ultimately, in the in vivo tumor xenograft zebrafish model, rilmenidine reduced the metastatic spread of pancreatic cancer cells. Our results suggest that NISCH agonist rilmenidine is a promising candidate for drug repurposing as an antimetastatic agent in PDAC and that NISCH can be a potential target for the development of new PDAC therapeutics.
- Open Access
- 15 July 2025
- Published by Elsevier in Seminars in Cancer Biology
- Vol. 114, 242-255
CRISPR/Cas9 genome engineering in PDAC: From preclinical studies to translation and clinical research
- 15 July 2025
- Published by Elsevier in Seminars in Cancer Biology
- Vol. 114, 242-255
Open AccessCRISPR/Cas9 genome engineering in PDAC: From preclinical studies to translation and clinical research
- Open Access
- 25 December 2024
- Published by Elsevier in Seminars in Cancer Biology
- Vol. 109, 10-24
Organoids, tissue slices and organotypic cultures: Advancing our understanding of pancreatic ductal adenocarcinoma through in vitro and ex vivo models
- 25 December 2024
- Published by Elsevier in Seminars in Cancer Biology
- Vol. 109, 10-24
Open AccessOrganoids, tissue slices and organotypic cultures: Advancing our understanding of pancreatic ductal adenocarcinoma through in vitro and ex vivo models